RESTON,
Va., Oct. 31, 2024 /PRNewswire/ --
Leidos (NYSE:LDOS) announced today a new contract to modernize
the Organ Procurement and Transplant Network (OPTN), a critical
system that delivers vital organ transplant information to
patients, donors, and healthcare providers. The contract was
awarded by the U.S. Department of Health and Human Services through
its Health Resources and Services Administration (HRSA). This
multiple-award, indefinite delivery/indefinite quantity contract
has a total potential value of $235
million, including a base period of performance of one-year
and four one-year option periods.
"Every 10 minutes, someone is added to the transplant waiting
list," said Liz Porter, Leidos
Health & Civil Sector president. "Patients, donors, families,
and physicians depend on timely and accurate data from the OPTN to
facilitate life-saving transplants. By providing improved access to
information and deploying modernized tools, we are dedicated to
equipping all involved with the resources they need to make
critical decisions."
Under the contract, Leidos will have the opportunity to compete
with other vendors to win tasks to modernize key pieces of the
organ transplant system to improve transparency, performance,
governance, and efficiency across the donation and transplantation
process. This effort will benefit more than 100,000 people on the
national organ transplant waitlist.
With its deep expertise in technology, health systems, and
large-scale electronic health record implementations, Leidos is
uniquely positioned to collaborate with HRSA on planning and
delivering the OPTN modernization.
This initiative, representing the most significant reforms of
the OPTN in nearly four decades, is aimed at improving health
outcomes and better-serving patients and families.
About Leidos
Leidos is a Fortune 500® innovation company rapidly
addressing the world's most vexing challenges in national security
and health. The company's global workforce of 48,000 collaborates
to create smarter technology solutions for customers in heavily
regulated industries. Headquartered in Reston, Virginia, Leidos reported annual
revenues of approximately $15.4
billion for the fiscal year ended December 29, 2023. For more information, visit
www.leidos.com.
Certain statements in this announcement constitute
"forward-looking statements" within the meaning of the rules and
regulations of the U.S. Securities and Exchange Commission
(SEC). These statements are based on management's current
beliefs and expectations and are subject to significant risks and
uncertainties. These statements are not guarantees of future
results or occurrences. A number of factors could cause our actual
results, performance, achievements, or industry results to be
different from the results, performance, or achievements expressed
or implied by such forward-looking statements. These factors
include, but are not limited to, the "Risk Factors" set forth in
Leidos' Annual Report on Form 10-K for the fiscal year ended
December 29, 2023, and other such
filings that Leidos makes with the SEC from time to
time. Readers are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date
hereof. Leidos does not undertake to update forward-looking
statements to reflect the impact of circumstances or events that
arise after the date the forward-looking statements were
made.
Contact:
Alyssa Pettus
(571) 526-6743
alyssa.t.pettus@leidos.com
Brandon VerVelde
(571) 526-6257
Brandon.p.vervelde@leidos.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leidos-awarded-organ-procurement-and-transplantation-network-operations-contract-302292139.html
SOURCE Leidos Holdings, Inc.